0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessCoronavirus disease 2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multi-organ manifestations. Lipid modulating agents may be useful in treating patients with COVID-19. They may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglycerides portends worse outcome in patients with COVID-19. Upon a systematic search, 40 RCTs with lipid modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrates RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for management or prevention of COVID-19. This manuscript summarizes the ongoing or completed randomized controlled trials (RCTs) of lipid modulating agents in COVID-19 and the implications of these trials for patient management.
Azita H. Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, Isaac Dreyfus, Hessam Kakavand, Hamid Ariannejad, Aakriti Gupta, Mahesh V. Madhavan, Benjamín W. Van Tassell, David González Jiménez, Manuel Monréal, Muthiah Vaduganathan, John Fanikos, Dave L. Dixon, Gregory Piazza, Sahil A. Parikh, Deepak L. Bhatt, Professor Gregory Lip, Gregg W. Stone, Harlan M. Krumholz, Peter Libby, Samuel Z. Goldhaber, Behnood Bikdeli (2021). Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials. , DOI: https://doi.org/10.1101/2021.05.03.21256468.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Preprint
Year
2021
Authors
23
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1101/2021.05.03.21256468
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
